



ATTORNEY DOCKET NO. 14014.0347U3
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
BERZOFSKY *et al.*)
Application No.: 10/770,117) Group Art Unit: 1642
Filed: February 2, 2004) Examiner: Unassigned
FOR: MODIFIED HCV PEPTIDE VACCINES) Confirmation No. 9347

PETITION FOR CORRECTION OF INVENTORSHIP IN PATENT APPLICATION,
PURSUANT TO 37 C.F.R. § 1.48(a)

Mail Stop Petition
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.
Customer No. 36339

Sir:

This application is a continuation application of U.S. Application No. 09/763,260, now U.S. Patent No. 6,685,944, issued February 3, 2004, in which a Petition for Correction of Inventorship in Patent Application, pursuant to 37 C.F.R. § 1.48(a) was granted May 17, 2002. Because the inventorship of the pending application is the same as the inventorship in U.S. Patent No. 6,685,944, applicants respectfully request that the inventorship be corrected accordingly.

Therefore, pursuant to 37 C.F.R. § 1.48(a), applicants hereby petition for correction of inventorship of the above-captioned patent application to delete Charles D. Pendleton and

**ATTORNEY DOCKET NO. 14014.0347U3
APPLICATION NO. 10/770,117**

Tatsumi Arichi as co-inventors. The inventorship originally set forth in the application was in error in naming Mr. Pendleton and Dr. Arichi, without deceptive intent on the part of the named inventors, nor on the part of any other party or parties.

The inventors of the present invention are Jay A. Berzofsky, Pablo Sarobe, Stephen M. Feinstone and Marian E. Major.

This petition is accompanied by a copy of the documents filed with the United States Patent and Trademark Office (PTO) in Application No. 09/763,260 and a copy of the documents mailed by the PTO to applicants in Application No. 09/763,260. These documents include the following:

- (1) a Petition for Correction of Inventorship in Patent Application Pursuant to 37 C.F.R. § 1.48(a), dated October 19, 2001, accompanied by:
 - (a) a statement from each person being deleted as an inventor that the error in inventorship occurred without deceptive intention on his part;
 - (b) a Declaration executed by the actual inventors pursuant to 37 C.F.R. § 1.63;
 - (c) the written consent of the assignee, The Government of the United States of America, as Represented by the Secretary, Department of Health and Human Services, National Institutes of Health, Office of Technology Transfer, as required under 37 C.F.R. § 1.48(a);
- (2) a Decision on Request Under 37 C.F.R. § 1.497(d), dated February 20, 2002;
- (3) a Renewed Petition for Correction of Inventorship in Patent Application Pursuant to 37 C.F.R. § 1.497(d), dated April 17, 2002, accompanied by:

**ATTORNEY DOCKET NO. 14014.0347U3
APPLICATION NO. 10/770,117**


to 37 C.F.R. § 1.497(d), dated April 17, 2002, accompanied by:

- (a) the Consent of Assignee; and
- (4) a Decision on Request Under 37 C.F.R. § 1.497(d), dated May 17, 2002, granting the petition.

A Credit Card Payment Form PTO-2038 authorizing payment in the amount of \$130.00 (fee for Petition under 37 C.F.R. § 1.17(i)) is enclosed. This amount is believed to be correct; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,


NEEDLE & ROSENBERG, P.C.



Bruce H. Becker, M.D., J.D.
Registration No. 48,884

NEEDLE & ROSENBERG, P.C.
999 Peachtree Street
Suite 1000
Atlanta, Georgia 30309-3915
678-420-9300
678-420-9301 (fax)

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Petition, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.


Bruce H. Becker, M.D., J.D.


Date



ATTORNEY DOCKET NO. 14014.0347U2
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
BERZOFSKY *et al.*)
Serial No.: 09/763,260) Group Art Unit: Unassigned
Filed: February 20, 2001) Examiner: Unassigned
FOR: MODIFIED HCV PEPTIDE VACCINE)

PETITION FOR CORRECTION OF INVENTORSHIP IN PATENT APPLICATION,
PURSUANT TO 37 C.F.R. § 1.48(a)

Commissioner for Patents
BOX PCT
Washington, D.C. 20231

NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811

October 19, 2001

Sir:

Pursuant to 37 C.F.R. §1.48(a), applicants hereby petition for correction of inventorship of the above-captioned patent application to delete Charles D. Pendleton and Tatsumi Arichi as co-inventors. The inventorship originally set forth in the application was in error in naming Mr. Pendleton and Dr. Arichi, without deceptive intent on the part of the named inventors, nor on the part of any other party or parties. The inventors of the present invention are Jay A. Berzofsky, Pablo Sarobe, Stephen M. Feinstone and Marian E. Major.

ATTORNEY DOCKET NO. 14014.0347U2
PATENT

This petition is accompanied by:

- (1) a statement from each person being deleted as an inventor that the error in inventorship occurred without deceptive intention on his part;
- (2) a Declaration executed by the actual inventors pursuant to 37 C.F.R. § 1.63;
- (3) the written consent of the assignee, The Government of the United States of America, as Represented by the Secretary, Department of Health and Human Services, National Institutes of Health, Office of Technology Transfer, as required under 37 C.F.R. § 1.48(a);
- (4) Request for Extension of Time;
- (5) a check in the amount of \$1,180.00 (\$130.00 surcharge under 37 C.F.R. § 1.16(e), \$130.00 surcharge under 37 C.F.R. § 1.17(i) and \$920.00 extension of time fee;
- (6) a Sequence Listing on Diskette;
- (7) Response to Notification of Missing Requirements Under 35 U.S.C. § 371;
- (8) a copy of the Notification of Missing Requirements Under 35 U.S.C. § 371;
- (9) a copy of the Notification to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures and;
- (10) a copy of the Notification of a Defective Oath or Declaration

ATTORNEY DOCKET NO. 14014.0347U2
PATENT

A check in the amount of \$1,180.00 (\$130.00 surcharge under C.F.R. § 1.16(e), \$130.00 surcharge under 37 C.F.R. § and \$920.00 extension of time fee) is attached. This amount is believed to be correct; however, the the Commissioner is hereby authorized to charge any additional fees due or credit any overpayment to Deposit Account 14-0629. Should there be any questions, please contact the undersigned at 404/688-0770.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.

Mary L. Miller

Mary L. Miller

Registration No. 39,303

NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811
404/688-0770

Express Mail No. EL 491587244US

Certificate of Express Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail Invoice No.491587244US in an envelope addressed to: Commissioner for Patents, BOX PCT, Washington, D.C. 20231, on the date shown below.

Eric Potter
Eric Potter

10-19-01

Date


ATTORNEY DOCKET NO. 14014.0347U2
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
BERZOFSKY et al.) Group Art Unit: Unassigned
Serial No.: 09/763,260) Examiner: Unassigned
Filed: February 20, 2001)
FOR: "MODIFIED HCV PEPTIDE VACCINE")

**STATEMENT OF CHARLES D. PENDLETON
ACCOMPANYING PETITION FOR CORRECTION OF INVENTORSHIP
IN PATENT APPLICATION, PURSUANT TO 37 C.F.R. § 1.48(a)**

I, Charles D. Pendleton, state that I am not a co-inventor of the invention, described and claimed in the above-captioned patent application, and that the error in my being named as an inventor occurred without deceptive intention on my part.



Charles D. Pendleton

ATTORNEY DOCKET NO. 14014.0347U2
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
BERZOFSKY *et al.*)
Serial No.: 09/763,260) Group Art Unit: Unassigned
Filed: February 20, 2001) Examiner: Unassigned
FOR: "MODIFIED HCV PEPTIDE VACCINE")

**STATEMENT OF TATSUMI ARICHI
ACCOMPANYING PETITION FOR CORRECTION OF INVENTORSHIP
IN PATENT APPLICATION, PURSUANT TO 37 C.F.R. § 1.48(a)**

I, Tatsumi Arichi, state that I am not a co-inventor of the invention, described and claimed in the above-captioned parent application, and that the error in my being named as an inventor occurred without deceptive intention on my part.

Tatsumi Arichi 10/10/2001

Tatsumi Arichi

**DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION**

Original Supplemental Substitute PCT

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled "MODIFIED HCV PEPTIDE VACCINE," which is described and claimed in the specification

- (check one) which is attached hereto, or
 which was filed on , as Application Serial No. and with amendments through
(if applicable), or
 in International Application No. PCT US99/18674, filed August 17, 1999, with
amendments as provided in the Preliminary Amendment filed on February 20, 2001.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information known by me to be material to the patentability of the claims of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code §119 (a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN APPLICATIONS (ENTER BELOW IF APPLICABLE)	PRIORITY CLAIMED (MARK APPROPRIATE BOX BELOW)			
APP. NUMBER	COUNTRY	DAY/MONTH/YEAR FILED	YES	NO
PCT/US99/18674	PCT	17 August 1999	<input checked="" type="checkbox"/>	<input type="checkbox"/>

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER	FILING DATE
60/097,446	21 August 1998

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information known by me to be material to the patentability of the claims of this application as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS (MARK APPROPRIATE COLUMN BELOW)		
		PATENTED	PENDING	ABANDONED

I hereby appoint the following attorneys to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected therewith:

James C. Haight, Reg. No. 25,588, Robert Benson, 33,612, Jack Spiegel, 34,477, Susan S. Rucker, 35,762, David R. Sadowski, 32,808, Steve Ferguson, 38,448; John Peter Kim, 38,514, Stephen L. Finley, 36,357, Norbert Pontzer, 40,777, Richard U. Rodriguez, 45,980, and Marlene Shinn, 46,005.


Address all telephone calls to Mary L. Miller at telephone no. (404) 688-0770.

Address all correspondence to:

Mary L. Miller, Ph.D.
NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor: Jay A. Berzofsky

Inventor's signature: 

Date: 10/13/01

Residence: 5908 Bradley Boulevard, Bethesda, MD 20814-1107

Post Office Address: 5908 Bradley Boulevard, Bethesda, MD 20814-1107

Citizenship: United States

Full name of second inventor: Stephen M. Feinstone

Inventor's signature: _____

Date: _____

Residence: 3021 Cathedral Avenue, Washington, D.C. 20008

Post Office Address: 3021 Cathedral Avenue, Washington, D.C. 20008

Citizenship: United States

Full name of third inventor: Marian E. Major

Inventor's signature: _____

Date: _____

Residence: 6608 Potomac Avenue, Apt. B2, Alexandria VA 22307

Post Office Address: 6608 Potomac Avenue, Apt. B2, Alexandria, VA 22307

Citizenship: United Kingdom

Full name of fourth inventor: Pablo Sarobe

Inventor's signature: _____

Date: _____

Residence: C/San Fermin 59 2D, 31003 Pamplona, Spain

Post Office Address: C/San Fermin 59 2D, 31003 Pamplona, Spain

Citizenship: Spain

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

(X) Original

() Supplemental

() Substitute

() PCT

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled "MODIFIED HCV PEPTIDE VACCINE," which is described and claimed in the specification

- (check one) [] which is attached hereto, or
[] which was filed on , as Application Serial No. and with amendments through
(if applicable), or
[X] in International Application No. PCT US99/18674, filed August 17, 1999, with
amendments as provided in the Preliminary Amendment filed on February 20, 2001.

I hereby state that I have reviewed and understand the contents of the above identified specification,
including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information known by me to be material to the patentability of the
claims of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code §119-(a)-(d) or §365(b) of any
foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application
which designated at least one country other than the United States of America, listed below and have also
identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any
PCT international application having a filing date before that of the application on which priority is
claimed:

PRIOR FOREIGN APPLICATIONS (ENTER BELOW IF APPLICABLE)			PRIORITY CLAIMED (MARK APPROPRIATE BOX BELOW)	
APP. NUMBER	COUNTRY	DAY/MONTH/YEAR FILED	YES	NO
PCT/US99/18674	PCT	17 August 1999	X	

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER	FILED DATE
60/097,446	21 August 1998

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information known by me to be material to the patentability of the claims of this application as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS (MARK APPROPRIATE COLUMN BELOW)		
		PATENTED	PENDING	ABANDONED

I hereby appoint the following attorneys to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected therewith:

James C. Haight, Reg. No. 25,588, Robert Benson, 33,612, Jack Spiegel, 34,477, Susan S. Rucker, 35,762, David R. Sadowski, 32,808, Steve Ferguson, 38,448; John Peter Kim, 38,514, Stephen L. Finley, 36,357, Norbert Pontzer, 40,777, Richard U. Rodriguez, 45,980, and Marlene Shinn, 46,005.

Address all telephone calls to Mary L. Miller at telephone no. (404) 688-0770.

Address all correspondence to:

Mary L. Miller, Ph.D.
NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor: Jay A. Berzofsky

Inventor's signature: _____ Date: _____

Residence: 5908 Bradley Boulevard, Bethesda, MD 20814-1107

Post Office Address: 5908 Bradley Boulevard, Bethesda, MD 20814-1107

Citizenship: United States

Full name of second inventor: Stephen M. Feinstone

Inventor's signature: _____ Date: _____

Residence: 3021 Cathedral Avenue, Washington, D.C. 20008

Post Office Address: 3021 Cathedral Avenue, Washington, D.C. 20008

Citizenship: United States

Full name of third inventor: Marian E. Major


Inventor's signature: _____ Date: _____

Residence: 6608 Potomac Avenue, Apt. B2, Alexandria VA 22307

Post Office Address: 6608 Potomac Avenue, Apt. B2, Alexandria, VA 22307

Citizenship: United Kingdom

Full name of fourth inventor: Pablo Sarobe

Inventor's signature: 

Date: October 15th 2001

Residence: C/San Fermin 59 2D, 31003 Pamplona, Spain

Post Office Address: C/San Fermin 59 2D, 31003 Pamplona, Spain

Citizenship: Spain

**DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION**

(X) Original

() Supplemental

() Substitute

() PCT

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled "MODIFIED HCV PEPTIDE VACCINE," which is described and claimed in the specification

- (check one) [] which is attached hereto, or
[] which was filed on , as Application Serial No. and with amendments through
(if applicable), or
[X] in International Application No. PCT US99/18674, filed August 17, 1999, with
amendments as provided in the Preliminary Amendment filed on February 20, 2001.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose all information known by me to be material to the patentability of the claims of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code §119 (a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN APPLICATIONS (ENTER BELOW IF APPLICABLE)			PRIORITY CLAIMED (MARK APPROPRIATE BOX BELOW)	
APP. NUMBER	COUNTRY	DAY/MONTH/YEAR FILED	YES	NO
PCT/US99/18674	PCT	17 August 1999	X	

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

APPLICATION NUMBER	FILING DATE
60/097,446	21 August 1998

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose all information known by me to be material to the patentability of the claims of this application as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

APPLICATION SERIAL NO.	FILING DATE	STATUS (MARK APPROPRIATE COLUMN BELOW)		
		PATENTED	PENDING	ABANDONED

I hereby appoint the following attorneys to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected therewith:

James C. Haight, Reg. No. 25,588, Robert Benson, 33,612, Jack Spiegel, 34,477, Susan S. Rucker, 35,762, David R. Sadowski, 32,808, Steve Ferguson, 38,448; John Peter Kim, 38,514, Stephen L. Finley, 36,357, Norbert Pontzer, 40,777, Richard U. Rodriguez, 45,980, and Marlene Shinn, 46,005.

Address all telephone calls to Mary L. Miller at telephone no. (404) 688-0770.

Address all correspondence to:

Mary L. Miller, Ph.D.
NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor: Jay A. Berzofsky


Inventor's signature: _____ Date: _____

Residence: 5908 Bradley Boulevard, Bethesda, MD 20814-1107

Post Office Address: 5908 Bradley Boulevard, Bethesda, MD 20814-1107

Citizenship: United States

Full name of second inventor: Stephen M. Feinstone

Inventor's signature:  Date: 10-12-01

Residence: 3021 Cathedral Avenue, Washington, D.C. 20008

Post Office Address: 3021 Cathedral Avenue, Washington, D.C. 20008

Citizenship: United States

Full name of third inventor: Marian E. Major

Inventor's signature:  Date: 10-12-01

Residence: 6608 Potomac Avenue, Apt. B2, Alexandria VA 22307

Post Office Address: 6608 Potomac Avenue, Apt. B2, Alexandria, VA 22307

Citizenship: United Kingdom

Full name of fourth inventor: Pablo Sarobe

Inventor's signature: _____ Date: _____

Residence: C/San Fermin 59 2D, 31003 Pamplona, Spain

Post Office Address: C/San Fermin 59 2D, 31003 Pamplona, Spain

Citizenship: Spain

ATTORNEY DOCKET NO. 14014.0347U2
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
BERZOFSKY et al.) Group Art Unit: Unassigned
Serial No.: 09/763,260) Examiner: Unassigned
Filed: February 20, 2001)
FOR: "MODIFIED HCV PEPTIDE VACCINE")

CONSENT OF ASSIGNEE,
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED
BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES,
NATIONAL INSTITUTES OF HEALTH, OFFICE OF TECHNOLOGY TRANSFER
ACCOMPANYING PETITION FOR CORRECTION OF INVENTORSHIP IN PATENT
APPLICATION, PURSUANT TO 37 C.F.R. §1.48(a)

The Government of the United States of America, as Represented by the Secretary, Department of Health and Human Services, National Institutes of Health, Office of Technology Transfer, assignee of the above-captioned patent application, hereby provides its written consent for correction of inventorship in said application to delete Charles D. Pendleton and Tatsumi Arichi as co-inventors.

National Institutes of Health

Robert Benson

by: Robert Benson, Ph.D.

title: Supervisor, Infectious Disease and
Medical Engineering Group



FEB 20 2002

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

Mary L. Miller
Needle & Rosenberg, P.C.
127 Peachtree Street, N.E., Suite 1200
Atlanta, GA 30303

MLM/GDS/BHB

DOCKETED	
By:	CW
Date: 2-26-02	
Reviewed:	Feb 27/02
Normal Priority	

RECEIVED

FEB 25 2002

NEEDLE & ROSENBERG

In re Application of
BERZOFSKY, Jay A., et al.
Application No.: 09/763,260
PCT No.: PCT/US99/18674
Int. Filing Date: 17 August 1999
Priority Date: 21 August 1998
Attorney's Docket No.: 14014.0347U2
For: MODIFIED HCV PEPTIDE VACCINE

DECISION

ON PETITION UNDER

37 CFR 1.497(d)

This is a decision on "Petition For Correction of Inventorship In Patent Application, Pursuant to 37 C.F.R. §1.48(a)," filed on 19 October 2001. The petition under 37 CFR 1.48(a) is being treated as a petition under 37 CFR 1.497(d).

BACKGROUND

On 17 August 1999, applicants filed international application PCT/US99/18674, which claimed a priority date of 21 August 1998. A copy of the international application was communicated to the United States Patent and Trademark Office (USPTO) from the International Bureau on 02 March 2000. On 17 February 2000, applicants filed a demand for international preliminary examination which elected the United States, prior to nineteen months from the priority date. The deadline for entry into the national stage in the United States was midnight 21 February 2001.

On 20 February 2001, applicants filed a submission for entry into the national stage in the United States which was accompanied by, *inter alia*, the U.S. Basic National Fee and a declaration executed by five inventors.

On 21 May 2001, the Office mailed, *inter alia*, a Notification of Missing Requirements (Form PCT/DO/EO/905) and a Notification of a Defective Oath or Declaration (Form PCT/DO/EO/917) indicating, *inter alia*, that the declaration was defective because it did not properly identify the inventors.

On 19 October 2001, applicants filed "Response to Notification of Missing Requirements," including, *inter alia*, the instant petition and a declaration executed by four inventors.

DISCUSSION

Under 37 CFR 1.41(a)(4), the inventors who submitted an application under §1.494 or §1.495 are the inventors in the international application designating the United States. The inventors in the international application include the inventors named upon filing of the international application or resulting from any changes made under Rule 92bis in the international stage. The record does not reflect any such requests under Rule 92bis during the international stage.

The inventors in the international application are Jay A. Berzofsky, Pablo Sarobe, C. David Pendleton, Stephen M. Feinstone, Tatsumi Arichi, and Marian Major. Applicants state that "the inventorship originally set forth in the application was in error in naming Mr. Pendleton and Dr. Arichi, without deceptive intent on the part of the named inventors, nor on the part of any other party or parties."

A petition under 37 CFR 1.497(d) requires: (1) a statement from each person being added as an inventor and from each person being deleted as an inventor that any error in inventorship in the international application occurred without deceptive intention on his or her part; (2) the processing fee set forth in §1.17(i); and (3) the written consent of the assignee, if an original named inventor has executed an assignment.

Items (1) and (2) have been met. (1) Applicants provided letters signed by Charles D. Pendleton and Tatsumi Arichi indicating that the error in each being named on the international application occurred without deceptive intention. (2) The processing fee set forth in §1.17(i) has been paid.

As to item (3), the written consent of assignee the United States of America is ineffective as signed by Robert Benson. First, applicants must furnish proof that the United States government is the assignee. Second, Dr. Benson's title of "Supervisor" is not one that sets him forth as an officer of the assigned and he is not presumed to have authority to sign the submission on behalf of the assignee. MPEP §324. The submission can either state that the signor is authorized to act on behalf of the assignee or "the submission may be signed by a person empowered by an organizational resolution ... to sign the submission on behalf of the assignee, if a copy of the resolution is, or was previously, submitted in the record." MPEP §324. Evidence of Dr. Benson's authority to sign is required.

CONCLUSION

For the above reasons, applicant's petition under 37 CFR 1.497(d) is DISMISSED, without prejudice.


If reconsideration on the merits of this petition is desired, a proper response must be filed within TWO (2) MONTHS from the mail date of this decision. Failure to timely file the proper

Application No.: 09/763,260


-3-

response will result in abandonment of this application. Any reconsideration request should include a cover letter entitled "Renewed Petition Under 37 CFR 1.497(d)". No additional petition fee is required.

Please direct any further correspondence with respect to this matter to the Commissioner of Patents and Trademarks, Box PCT, Washington, D.C. 20231, and address the contents of the letter to the attention of the Office of PCT Legal Administration.



Boris Milef
PCT Legal Examiner
PCT Legal Administration



Erin M. Pender
Attorney Advisor
PCT Legal Administration

Telephone: (703) 305-0455
Facsimile: (703) 308-6459

ATTORNEY DOCKET NO. 14014.0347U2
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
BERZOFSKY *et al.*) Group Art Unit: Unassigned
Serial No.: 09/763,260) Examiner: Unassigned
Filed: February 20, 2001)
FOR: MODIFIED HCV PEPTIDE VACCINE)

RENEWED PETITION UNDER 37 C.F.R. § 1.497(d)

ATTN: Office of PCT Legal Administration
Commissioner for Patents
BOX PCT
Washington, D.C. 20231

NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811

April 17, 2002

Sir:

This is responsive to the February 20, 2002 Decision on Petition Under 37 C.F.R. § 1.497(d) which was issued regarding the above-referenced patent application. Enclosed herewith are a copy of the Decision, a substitute written consent of the assignee, and a copy of the Notice of Recordation of Assignment (including the Assignment transmittal and the executed Assignment) by which the inventors have assigned their rights to the invention to The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services, National Institutes of Health, Office of Technology Transfer.

REMARKS

A petition to correct inventorship regarding the above-referenced patent application was filed on October 19, 2001. On February 20, 2002, a Decision on Petition under 37 C.F.R. § 1.497(d) was issued, dismissing applicants' petition. The Decision noted that a petition under 37 C.F.R. § 1.497(d) requires (1) a statement from each person being added as an inventor and from

ATTORNEY DOCKET NO. 14014.0347U2
PATENT

each person being deleted as an inventor that an error in inventorship in the international application occurred without deceptive intention on his or her part; (2) the processing fee set forth in 37 C.F.R. § 1.17(i); and (3) the written consent of the assignee, if an original named inventor has executed an assignment.

The Decision acknowledges that items (1) and (2) have been met. However, item (3), the written consent of the assignee is deemed ineffective. The Decision states that applicants must furnish proof that the United States Government is the assignee and show that the person signing the consent has the authority to sign the submission on behalf of the assignee. MPEP § 324.

On March 27, 2002, applicants' attorney telephoned Legal Administrator Ms. Erin Pender and confirmed that submitting the following items would correct the deficiencies in the October 19, 2001 petition and satisfy the remaining requirements under 37 C.F.R. § 1.47(d):

- (1) A copy of the Notice of Recordation of Assignment, Assignment Transmittal, and an executed Assignment regarding the pending application;
- (2) A copy of the Decision on Petition Under 37 C.F.R. § 1.47(d); and
- (3) A substitute written consent of the assignee, The Government of the United States of America, as Represented by the Secretary, Department of Health and Human Services, National Institutes of Health, Office of Technology Transfer, including a statement that the signor is authorized to act on behalf of the assignee.


Applicants herewith submit the three (3) aforementioned documents and respectfully request reconsideration and allowance of the previously submitted Petition Under 37 C.F.R. § 1.47(d).

ATTORNEY DOCKET NO. 14014.0347U2
PATENT

No amount is believed due; however, the Commissioner is hereby authorized to charge any fees due or credit any overpayment to Deposit Account 14-0629. Should there be any questions, please contact the undersigned at 404/688-0770.

Respectfully submitted,

NEEDLE & ROSENBERG, P.C.



Mary L. Miller


Registration No. 39,303

NEEDLE & ROSENBERG, P.C.
Suite 1200, The Candler Building
127 Peachtree Street, N.E.
Atlanta, Georgia 30303-1811
404/688-0770

Certificate of Express Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail Invoice No.403505525US
in an envelope addressed to: ATTN: Office of PCT Legal Administration, Commissioner for Patents, BOX PCT, Washington, D.C.
20251, on the date shown below.


David Thorpe


Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
BERZOFSKY *et al.*)
Serial No. 09/763,260) Group Art Unit: Unassigned
Filed: February 20, 2001) Examiner: Unassigned
FOR: "MODIFIED HCV PEPTIDE VACCINE")

CONSENT OF ASSIGNEE,
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED
BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES,
NATIONAL INSTITUTES OF HEALTH, OFFICE OF TECHNOLOGY TRANSFER
ACCOMPANYING PETITION FOR CORRECTION OF INVENTORSHIP IN PATENT
APPLICATION, PURSUANT TO 37 C.F.R. §1.48(a)

The Government of the United States of America, as Represented by the Secretary, Department of Health and Human Services, National Institutes of Health, Office of Technology Transfer, is assignee of the above-referenced patent application, as evidenced by the attached copy of an Assignment from JAY A. BERZOFSKY, PABLO SAROBE, C. DAVID PENDLETON, STEPHEN M. FEINSTONE AND MARIAN E. MAJOR to the Government of the United States of America, as represented by the Secretary, Department of Health and Human Services, Office of Technology Transfer, which Assignment has been recorded with the U.S. Patent and Trademark Office at Reel/Frame 011933/0515 on June 28, 2001.

As a representative authorized to act on behalf of the assignee, I hereby provide consent for correction of inventorship in the above-referenced application to delete Charles D. Pendleton and Tatsumi Arichi as co-inventors. I further certify that I am authorized to sign this document on behalf of the assignee.

National Institutes of Health

By Jack Spiegel
By Jack Spiegel, Ph.D.

Title: Director, Division of Technology Development
and Transfer



MAY 17 2002

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

RECEIVED

MAY 20 2002

NEEDLE & ROSENBERG

Mary L. Miller
Needle & Rosenberg, P.C.
127 Peachtree Street, N.E., Suite 1200
Atlanta, GA 30303

In re Application of
BERZOFSKY, Jay A., et al.
Application No.: 09/763, 260
PCT No.: PCT/US99/18674
Int. Filing Date: 17 August 1999
Priority Date: 21 August 1998
Attorney's Docket No.: 14014.0347U2
For: MODIFIED HCV PEPTIDE VACCINE

MLM/BDS/BHB/jwh
1/2/02 DECISION
MLM 5/24/02 ON REQUEST UNDER

37 CFR 1.497(d)

This is a decision on "Renewed Petition Under 37 C.F.R. §1.497(d)," filed 17 April 2002.

BACKGROUND

On 17 August 1999, applicants filed international application PCT/US99/18674, which claimed a priority date of 21 August 1998. A copy of the international application was communicated to the United States Patent and Trademark Office (USPTO) from the International Bureau on 02 March 2000. On 17 February 2000, applicants filed a demand for international preliminary examination which elected the United States, prior to nineteen months from the priority date. The deadline for entry into the national stage in the United States was midnight 21 February 2001.

On 20 February 2001, applicants filed a submission for entry into the national stage in the United States, which was accompanied by, *inter alia*, the U.S. Basic National Fee and a declaration executed by five inventors.

On 21 May 2001, the Office mailed, *inter alia*, a Notification of Missing Requirements (Form PCT/DO/EO/905) and a Notification of a Defective Oath or Declaration (Form PCT/DO/EO/917) indicating, *inter alia*, that the declaration was defective because it did not properly identify the inventors.

On 19 October 2001, applicants filed "Response to Notification of Missing Requirements," including, *inter alia*, the request and a declaration executed by four inventors.

On 20 February 2002, the Office mailed Decision On Petition Under 37 CFR 1.497(d), refusing applicants' request for failure to provide written consent of the assignee.

On 17 April 2002, applicants submitted "Renewed Petition Under 37 C.F.R. §1.497(d)," accompanied by, *inter alia*, copies of assignments and a new consent of the assignee.

AND

Application No.: 09/763,260

-2-

DISCUSSION

A request under 37 CFR 1.497(d) requires: (1) a statement from each person being added as an inventor and from each person being deleted as an inventor that any error in inventorship in the international application occurred without deceptive intention on his or her part; (2) the processing fee set forth in §1.17(i); and (3) the written consent of the assignee, if an original named inventor has executed an assignment.


Items (1) and (2) were previously met.

Item (3) has now been met. Applicants have provided copies of the assignments and a new written consent from the assignee, the United States government. Jack Spiegel signed on behalf of the government and indicated that he has the authority to do so.


CONCLUSION

For the above reasons, applicants' request under 37 CFR 1.497(d) is **GRANTED**.

The application has an international filing date of 17 August 1999 under 35 U.S.C. §363 and a date of 19 October 2001 under 35 U.S.C. §371. This application is being forwarded to the National Stage Processing Division of the Office of the PCT Operations for continued processing.



Richard Cole
PCT Legal Examiner
PCT Legal Administration



Erin M. Pender
Attorney Advisor
PCT Legal Administration

Telephone: (703) 305-0455
Facsimile: (703) 308-6459